Authors:
Economou C, Tsakiridis A, Wymeersch FJ, Gordon-Keylock S, Dewhurst RE, Fisher D, et al.
Authors notes:
BMC Dev Biol. 2015;15(1):35.
Keywords:
Extragonadal teratoma, Pluripotency, Oct4, Nanog, Brachyury, Inducible, expression
Abstract:
BACKGROUND: Pluripotent cells are present in early embryos until the levels of the pluripotency regulator Oct4 drop at the beginning of somitogenesis.
Elevating Oct4 levels in explanted post-pluripotent cells in vitro restores their pluripotency.
Cultured pluripotent cells can participate in normal development when introduced into host embryos up to the end of gastrulation.
In contrast, pluripotent cells efficiently seed malignant teratocarcinomas in adult animals.
In humans, extragonadal teratomas and teratocarcinomas are most frequently found in the sacrococcygeal region of neonates, suggesting that these tumours originate from cells in the posterior of the embryo that either reactivate or fail to switch off their pluripotent status.
However, experimental models for the persistence or reactivation of pluripotency during embryonic development are lacking.
METHODS: We manually injected embryonic stem cells into conceptuses at E9.5 to test whether the presence of pluripotent cells at this stage correlates with teratocarcinoma formation.
We then examined the effects of reactivating embryonic Oct4 expression ubiquitously or in combination with Nanog within the primitive streak (PS)/tail bud (TB) using a transgenic mouse line and embryo chimeras carrying a PS/TB-specific heterologous gene expression cassette respectively.
RESULTS: Here, we show that pluripotent cells seed teratomas in post-gastrulation embryos.
However, at these stages, induced ubiquitous expression of Oct4 does not lead to restoration of pluripotency (indicated by Nanog expression) and tumour formation in utero, but instead causes a severe phenotype in the extending anteroposterior axis.
Use of a more restricted T(Bra) promoter transgenic system enabling inducible ectopic expression of Oct4 and Nanog specifically in the posteriorly-located primitive streak (PS) and tail bud (TB) led to similar axial malformations to those induced by Oct4 alone.
These cells underwent induction of pluripotency marker expression in Epiblast Stem Cell (EpiSC) explants derived from somitogenesis-stage embryos, but no teratocarcinoma formation was observed in vivo.
CONCLUSIONS: Our findings show that although pluripotent cells with teratocarcinogenic potential can be produced in vitro by the overexpression of pluripotency regulators in explanted somitogenesis-stage somatic cells, the in vivo induction of these genes does not yield tumours.
This suggests a restrictive regulatory role of the embryonic microenvironment in the induction of pluripotency.